Citi Pharma ventures into direct marketing sector
Company aims to improve medicine accessibility and expand globally
Citi Pharma partners with Mersi Farma to establish advanced API plants in Indonesia
Collaboration to bolster pharmaceutical production and expand nutraceutical market
Despite deregulated prices, Searle swings to a loss
Price increases were not enough to compensate for increases in operating costs, despite a gross profit margin expansion
Drug price deregulation has come to Pakistan. What will this mean?
Companies can finally raise prices, which is likely to result in higher prices, but also likely to mean fewer shortages of essential drugs
Citi Pharma enters into joint venture to establish API, formulation facility in Saudi Arabia
Joint venture will focus on manufacturing essential APIs and formulation products to meet the healthcare needs of the KSA and the broader MENA region
Ferozsons strikes deal with Gilead Sciences to produce generic HIV drugÂ
Ferozsons or its affiliates can manufacture and sell lenacapavir in 120 countriesÂ
BF Bioscience, pharma company owned by Ferozsons and Argentinian Bago Group, got a stellar response to its IPO. What lies ahead?Â
The pharma company, which has been exporting to countries like Indonesia, Belarus and Ukraine, saw book building at Rs 77/share and oversubscription of 3.4 times.
Citi Pharma gets FDA nod to start exporting nutraceuticals to the United States
The pharmaceutical ingredients manufacturer enters the consumer-facing market in the US with a product the US regulator classifies as food, and not drugs
BF Biosciences expands production, launches diabetes treatment, secures listing approval
Company receives approval for brownfield expansion and launches Sematide, a new diabetes treatment, while listing application is greenlit by SECP and PSX
PPMA strongly refutes allegations against quality of Pakistani medicines
Pharmaceutical body defends industry standards, warns against harmful impact on exports and national reputation
Pharmaceutical exports surge by 30% in July 2024
Significant growth observed in both value and quantity of exports.
In the first quarter after deregulation, pharma sector revenue up by 25%
The increase in revenue is driven mostly by price increases as drug manufacturers can finally raise prices based on business need and rising costs instead of regulatory fiat
Ferozsons launches biologic to treat diabetes
Pharmaceutical company’s biotech subsidiary to launch the new product in one of Pakistan’s biggest therapeutic areas
Ferozsons subsidiary launches human insulin
Company says Ferulin, developed with the highest quality standards, will provide effective and affordable diabetes treatment to patientsÂ
BF Biosciences plans to raise Rs 1.37 billion through IPOÂ
IPO will consist of 25 million ordinary shares with floor price of PKR 55 per share